
Simon J Bowman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2337462/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 9-16.	0.9	959
2	EULAR SJĶgren's syndrome disease activity index: development of a consensus systemic disease activity index for primary SJĶgren's syndrome. Annals of the Rheumatic Diseases, 2010, 69, 1103-1109.	0.9	734
3	Sjögren syndrome. Nature Reviews Disease Primers, 2016, 2, 16047.	30.5	511
4	Variants at multiple loci implicated in both innate and adaptive immune responses are associated with SjĶgren's syndrome. Nature Genetics, 2013, 45, 1284-1292.	21.4	427
5	EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2011, 70, 968-972.	0.9	383
6	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Annals of the Rheumatic Diseases, 2020, 79, 3-18.	0.9	307
7	Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sj�gren's syndrome. Arthritis and Rheumatism, 2001, 44, 2633-2641.	6.7	264
8	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. RMD Open, 2015, 1, e000022-e000022.	3.8	229
9	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary SjA¶gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Annals of the Rheumatic Diseases, 2016, 75, 382-389.	0.9	225
10	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 1161-1168.	0.9	200
11	Randomized Controlled Trial of Rituximab and Costâ€Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2017, 69, 1440-1450.	5.6	194
12	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Annals of the Rheumatic Diseases, 2015, 74, 859-866.	0.9	193
13	Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. Annals of the Rheumatic Diseases, 2011, 70, 500-507.	0.9	192
14	Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health and Quality of Life Outcomes, 2009, 7, 46.	2.4	177
15	IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11024-11029.	7.1	173
16	Primary Sjogren's syndrome: too dry and too tired. Rheumatology, 2010, 49, 844-853.	1.9	119
17	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016, 12, 137-156.	3.0	118
18	Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13490-13497.	7.1	115

#	Article	IF	CITATIONS
19	Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity. Rheumatology, 2018, 57, 921-930.	1.9	102
20	Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology, 2015, 54, 836-843.	1.9	92
21	Classification criteria for SjĶgren's syndrome: we actually need to definitively resolve the long debate on the issue. Annals of the Rheumatic Diseases, 2013, 72, 476-478.	0.9	90
22	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. Annals of the Rheumatic Diseases, 2014, 73, 1362-1368.	0.9	87
23	Salivary gland ultrasound abnormalities in primary SjŶgren's syndrome: consensual US-SG core items definition and reliability. RMD Open, 2017, 3, e000364.	3.8	87
24	Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Annals of the Rheumatic Diseases, 2018, 77, 412-416.	0.9	86
25	A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker: TableÂ1. Annals of the Rheumatic Diseases, 2015, 74, 1645-1650.	0.9	85
26	Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma. Annals of the Rheumatic Diseases, 2020, 79, 1588-1599.	0.9	83
27	Outcome measures for primary Sjögren's syndrome: A comprehensive review. Journal of Autoimmunity, 2014, 51, 51-56.	6.5	77
28	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. RMD Open, 2016, 2, e000282.	3.8	77
29	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology, The, 2019, 1, e85-e94.	3.9	76
30	The IRF5–TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Human Molecular Genetics, 2015, 24, 582-596.	2.9	74
31	Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet, The, 2022, 399, 161-171.	13.7	72
32	Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatology, The, 2020, 2, e142-e152.	3.9	68
33	Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. Arthritis Care and Research, 2010, 62, 551-558.	3.4	66
34	United Kingdom Primary Sjogren's Syndrome Registrya united effort to tackle an orphan rheumatic disease. Rheumatology, 2011, 50, 32-39.	1.9	64
35	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. PLoS Genetics, 2017, 13, e1006820.	3.5	60
36	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary SjĶgren's syndrome. Annals of the Rheumatic Diseases, 2012, 71, 1973-1979.	0.9	57

#	Article	IF	CITATIONS
37	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Annals of the Rheumatic Diseases, 2016, 75, 1945-1950.	0.9	57
38	Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren's syndrome. Journal of Rheumatology, 2003, 30, 1259-66.	2.0	56
39	Classification criteria for Sjogren's syndrome: nothing ever stands still!. Annals of the Rheumatic Diseases, 2014, 73, 1-2.	0.9	54
40	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. RMD Open, 2019, 5, e001064.	3.8	53
41	Efficacy of Epratuzumab, an Antiâ€ <scp>CD</scp> 22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 763-773.	5.6	49
42	Outcome measures for primary Sjögren's syndrome. Journal of Autoimmunity, 2012, 39, 97-102.	6.5	46
43	Association of Genes in the <scp>NF</scp> â€̂₽B Pathway with Antibodyâ€Positive Primary Sjögren's Syndrome. Scandinavian Journal of Immunology, 2013, 78, 447-454.	2.7	45
44	The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren's Syndrome. BMC Musculoskeletal Disorders, 2014, 15, 21.	1.9	43
45	Estimating Indirect Costs in Primary Sjögren's Syndrome. Journal of Rheumatology, 2010, 37, 1010-1015.	2.0	42
46	The assessment of fatigue in primary Sjögren's syndrome. Scandinavian Journal of Rheumatology, 2003, 32, 33-37.	1.1	40
47	Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma. Annals of the Rheumatic Diseases, 2016, 75, 780-783.	0.9	40
48	Fatigue in primary Sjögren's syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. Rheumatology International, 2019, 39, 1867-1873.	3.0	35
49	The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. Rheumatology, 2017, 56, e24-e48.	1.9	33
50	Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome. Annals of the Rheumatic Diseases, 2019, 78, 249-260.	0.9	33
51	Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 2010, 69, 1731-1732.	0.9	31
52	Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatology, The, 2021, 3, e553-e562.	3.9	31
53	Rheumatoid Arthritis is Associated with IgG Antibodies to Human Endogenous Retrovirus Gag Matrix: A Potential Pathogenic Mechanism of Disease?. Journal of Rheumatology, 2014, 41, 1952-1960.	2.0	29
54	Periodontitis prevalence and serum antibody reactivity to periodontal bacteria in primary Sjögren's syndrome: a pilot study. Journal of Clinical Periodontology, 2016, 43, 26-33.	4.9	29

#	Article	IF	CITATIONS
55	Candidate T cell epitopes of the human La/SSB autoantigen. Arthritis and Rheumatism, 2002, 46, 209-214.	6.7	27
56	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2022, 81, 979-989.	0.9	27
57	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj¶gren's syndrome. Rheumatology, 2021, 60, 1364-1375.	1.9	26
58	The value of histopathological examination of salivary gland biopsies in diagnosis, prognosis and treatment of Sjögren's Syndrome. Swiss Medical Weekly, 2015, 145, w14168.	1.6	26
59	Patient-Reported Outcomes Including Fatigue in Primary Sjögren's Syndrome. Rheumatic Disease Clinics of North America, 2008, 34, 949-962.	1.9	25
60	B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome. Rheumatology, 2018, 57, 1222-1227.	1.9	23
61	Do the EULAR Sjogren's syndrome outcome measures correlate with health status in primary Sjogren's syndrome?. Rheumatology, 2015, 54, 655-659.	1.9	22
62	A new MHC-linked susceptibility locus for primary Sjögren's syndrome: MICA. Human Molecular Genetics, 2017, 26, 2565-2576.	2.9	22
63	Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren's syndrome. Rheumatology International, 2020, 40, 541-548.	3.0	22
64	Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. Journal of Rheumatology, 2005, 32, 143-9.	2.0	21
65	Mixedâ€Methods Study Identifying Key Intervention Targets to Improve Participation in Daily Living Activities in Primary SjA¶gren's Syndrome Patients. Arthritis Care and Research, 2018, 70, 1064-1073.	3.4	15
66	Biologic treatments in Sjögren's syndrome. Presse Medicale, 2012, 41, e495-e509.	1.9	14
67	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. RMD Open, 2019, 5, e000885.	3.8	14
68	The development and initial validation of the Liverpool sicca index to assess symptoms and dysfunction in patients with primary SjĶgren's syndrome. Journal of Oral Pathology and Medicine, 2003, 32, 154-162.	2.7	13
69	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. Rheumatology, 2015, 55, kev373.	1.9	9
70	Scleritis as the presenting sign of primary antiphospholipid syndrome. Eye, 2001, 15, 558-559.	2.1	8
71	Biological therapies in primary Sjögren's syndrome. Expert Opinion on Biological Therapy, 2011, 11, 921-936.	3.1	8
72	NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. Frontiers in Immunology, 2021, 12, 706737.	4.8	8

#	Article	IF	CITATIONS
73	Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction. Communications Biology, 2022, 5, 413.	4.4	8
74	Disease activity and patient reported outcome measures in Sjögren's – what are the best tools to evaluate?. Rheumatology, 2019, , .	1.9	7
75	B cell depletion with rituximab in the treatment of primary Sjögren's syndrome: what have we learnt?. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 217-224.	0.8	7
76	Outcome Measures in Primary Sjögren's Syndrome. Arthritis Care and Research, 2020, 72, 134-149.	3.4	6
77	Stratifying primary Sjögren's syndrome: killers in the balance?. Arthritis Research and Therapy, 2015, 17, 351.	3.5	4
78	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. Drugs and Aging, 2021, 38, 265-284.	2.7	4
79	Mediterranean diet and risk of Sjögren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 216-221.	0.8	4
80	SP0190â€2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJöGRENâ€S SYNDROME WITH TO AND SYSTEMIC THERAPIES. , 2019, , .	PICAL	3
81	FRI0652â€SERUM CXCL13 LEVELS ARE ASSOCIATED WITH LYMPHOMA RISK AND LYMPHOMA OCCURRENCE PRIMARY SJöGREN'S SYNDROME. , 2019, , .	IN	1
82	Ectopic expression of the B cell–attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center–like structures in Sjögren's syndrome. , 2001, 44, 2633.		1
83	Sjögren's and non-Sjögren's sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature. RMD Open, 2022, 8, e002119.	3.8	1
84	215. Cognitive Impairment in Primary Sjögren's Syndrome. Rheumatology, 0, , .	1.9	0
85	I115â \in f Trials and Tribulations of B Cell Therapies (Tractiss). Rheumatology, 0, , .	1.9	0
86	The national clinical audit for rheumatoid and early inflammatory arthritis. Clinical Medicine, 2016, 16, 500-501.	1.9	0
87	The healthcare quality improvement partnership national early arthritis audit. Rheumatology, 2017, 56, 171-172.	1.9	0
88	Clinical Aspects of Sjögren's. , 2019, , 566-578.		0
89	History of tonsillectomy is associated with glandular inflammation in Sjögren's disease. Rheumatology, 2022, , .	1.9	0
90	Acceptability of donor funding for clinical trials in the UK: a qualitative empirical ethics study using focus groups to elicit the views of research patient public involvement group members, research ethics committee chairs and clinical researchers. BMJ Open, 2022, 12, e055208.	1.9	0